ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 21 Issue : 1
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients? [Anatol J Cardiol]
Anatol J Cardiol. Ahead of Print: AJC-25564 | DOI: 10.14744/AnatolJCardiol.2018.25564  

Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?

Mustafa Tarık Ağaç1, Behlül Kahyaoğlu1, Muhammed Murat Necati Aksoy1, Fatma Behice Cinemre2, Mehmet Bülent Vatan1, Yasemin Gündüz3
1Department of Cardiology, Faculty of Medicine, Sakarya University; Sakarya-Turkey
2Department of Biochemistry, Faculty of Medicine, Sakarya University; Sakarya-Turkey
3Department of Radiology, Faculty of Medicine, Sakarya University; Sakarya-Turkey

Objective: Identification of the asymptomatic target organ damage (AOD) helps to stratify the overall risk of cardiovascular (CV) diseases and
guides a treatment decision in hypertensive patients without a symptomatic CV or renal disease. The endothelial-cell-specific molecule 1
(endocan) is regarded as a novel marker of endothelial dysfunction. Its release is increased in hypertensive patients, especially those with
symptomatic CV and renal disease. In the present study, we aimed to evaluate the endocan levels in asymptomatic hypertensive patients with
or without AOD.
Methods: The study included 132 asymptomatic hypertensive patients, and 101 of who had at least one AOD.
Results: Serum endocan levels did not differ between patients with and without AOD (3.81±0.78 vs. 3.83±0.63 ng/mL, p=0.88). An analysis according to the presence of any specific AOD did not show any difference between groups. No significant correlation was found between serum endocan levels and any of the continuous variables related to AOD, such as the pulse pressure, carotid intimae-media thickness, cardio-ankle vascular index, ankle-brachial index, left ventricular mass index, Sokolow–Lyon index, Cornell voltage-duration product, and estimated glomerular filtration rate.
Conclusion: Endocan may not serve as a useful biomarker at asymptomatic vascular stages of hypertension, despite its role in indicating disease severity and inflammatory activation in advanced symptomatic CV and renal disease.

Keywords: endocan, asymptomatic target organ damage, hypertension




Corresponding Author: Mustafa Tarık Ağaç, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology